Ariosa Diagnostics announced that it won summary judgment yesterday in patent infringement litigation against Sequenom, an exclusive licensee of the patent from Isis Innovations. The United States District Court for the Northern District of California invalidated the '540 patent at issue. The patent at issue is related to the detection of fetal cell-free DNA in the bloodstream of pregnant women, and Sequenom claimed that it applied to tests for the determination of certain fetal genetic characteristics, according to Ariosa. The Court invalidated Sequenom's patent because it attempts to cover this natural phenomenon, which the Court found is not patent-eligible subject matter, it added. Shares of Sequenom are down 9% to $2.26 in morning trading.